Stockscreener 앱 받기
38.34
6.10%
-2.49
시간 외 거래:
39.09
0.75
+1.96%
전일 마감가:
$40.83
열려 있는:
$40.85
하루 거래량:
1.37M
Relative Volume:
0.78
시가총액:
$4.03B
수익:
$741.17M
순이익/손실:
$104.65M
주가수익비율:
43.81
EPS:
0.8752
순현금흐름:
$162.57M
1주 성능:
-0.05%
1개월 성능:
+2.62%
6개월 성능:
-47.90%
1년 성능:
-45.35%
1일 변동 폭
$38.00
$40.85
1주일 범위
$38.00
$41.92
52주 변동 폭
$32.99
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
38.34 | 4.29B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) - GlobeNewswire
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M - Benzinga
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations - NewMediaWire
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is ... - Bluefield Daily Telegraph
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say - MSN
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - The Globe and Mail
Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - FinancialContent
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
FinancialContentCORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law Violations - The Globe and Mail
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then - Yahoo Finance
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Hold" by Brokerages - MarketBeat
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible FraudContact Levi & Korsinsky Today - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Published on: 2026-02-04 10:56:05 - baoquankhu1.vn
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutanix, Inc. - GlobeNewswire Inc.
Brown Capital Management LLC Makes New $19.95 Million Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations - NewMediaWire
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings - BioSpace
DJS Law Group Investigates Corcept Securities Violations - intellectia.ai
Rosen Law Firm Investigates Securities Claims for Corcept Shareholders - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares F - The National Law Review
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - NewMediaWire
Corcept Therapeutics Faces FDA Warning Over Drug Efficacy Claims - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing - The AI Journal
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
Berman Tabacco Announces Investigation of Corcept - GlobeNewswire
Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' - Fierce Biotech
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say - Stocktwits
CORT Sees Increased Call Options Activity - GuruFocus
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT - Business Wire
Commit To Purchase Corcept Therapeutics At $25, Earn 18.7% Annualized Using Options - Nasdaq
Corcept shares tumble after FDA letter reveals warnings before drug rejection - Yahoo! Finance Canada
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses - GlobeNewswire
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug A - GuruFocus
Corcept stock down as FDA revises CRL (CORT:NASDAQ) - Seeking Alpha
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코르셉트 테라퓨틱스 주식 (CORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Option Exercise |
21.65 |
20,000 |
433,000 |
21,235 |
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Sale |
40.87 |
20,000 |
817,334 |
1,235 |
1.24%
0.19%
자본화:
|
볼륨(24시간):